“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors
Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma which is often characterised by a pattern of continued relapse after frontline chemoimmunotherapy. Although patients are usually able to regain durable disease control with covalent Bruton’s tyrosine kinase inhibitors (cBTKi) at first...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2024-11-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11822 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846167421663051776 |
|---|---|
| author | Brian T. Grainger Chan Y. Cheah |
| author_facet | Brian T. Grainger Chan Y. Cheah |
| author_sort | Brian T. Grainger |
| collection | DOAJ |
| description |
Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma which is often characterised by a pattern of continued relapse after frontline chemoimmunotherapy. Although patients are usually able to regain durable disease control with covalent Bruton’s tyrosine kinase inhibitors (cBTKi) at first relapse, it is now appreciated that such responses are often not sustained and the management of such patients represents a significant area of unmet need. There is an imperative to better understand resistance mechanisms and identify high-risk subsets of patients for whom cBTKi responses may be particularly short. Allogeneic stem cell transplant has an established role in appropriate candidates, however contemporary consensus is to preferentially offer chimeric antigen receptor (CAR) T-cell therapy. In this Review, we consider the available data on both existing and emerging treatment options, including non-covalent BTK inhibitors, bispecific antibodies, antibody-drug conjugates and Bcl-2 inhibitors and propose a treatment strategy prioritising clinical trials where available.
|
| format | Article |
| id | doaj-art-e4bb7e68c56d4391b9ebe4fcc2481c87 |
| institution | Kabale University |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-e4bb7e68c56d4391b9ebe4fcc2481c872024-11-14T19:41:15ZengFerrata Storti FoundationHaematologica0390-60781592-87212024-11-01999110.3324/haematol.2024.286205“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitorsBrian T. Grainger0Chan Y. Cheah1Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WADepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; Linear Clinical Research, Nedlands, WA, Australia; Medical School, University of Western Australia, Nedlands, WA Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma which is often characterised by a pattern of continued relapse after frontline chemoimmunotherapy. Although patients are usually able to regain durable disease control with covalent Bruton’s tyrosine kinase inhibitors (cBTKi) at first relapse, it is now appreciated that such responses are often not sustained and the management of such patients represents a significant area of unmet need. There is an imperative to better understand resistance mechanisms and identify high-risk subsets of patients for whom cBTKi responses may be particularly short. Allogeneic stem cell transplant has an established role in appropriate candidates, however contemporary consensus is to preferentially offer chimeric antigen receptor (CAR) T-cell therapy. In this Review, we consider the available data on both existing and emerging treatment options, including non-covalent BTK inhibitors, bispecific antibodies, antibody-drug conjugates and Bcl-2 inhibitors and propose a treatment strategy prioritising clinical trials where available. https://haematologica.org/article/view/11822 |
| spellingShingle | Brian T. Grainger Chan Y. Cheah “The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors Haematologica |
| title | “The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors |
| title_full | “The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors |
| title_fullStr | “The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors |
| title_full_unstemmed | “The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors |
| title_short | “The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors |
| title_sort | the end of the golden weather therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent btk inhibitors |
| url | https://haematologica.org/article/view/11822 |
| work_keys_str_mv | AT briantgrainger theendofthegoldenweathertherapeuticstrategiesformantlecelllymphomarelapsedorrefractorytocovalentbtkinhibitors AT chanycheah theendofthegoldenweathertherapeuticstrategiesformantlecelllymphomarelapsedorrefractorytocovalentbtkinhibitors |